Autoantibody Selectively Inhibits Binding of von Willebrand Factor to Glycoprotein Ib. Recognition Site Is Located in the A1 Loop of von Willebrand Factor

Summary A 20-year-old man with severe von Willebrand disease recently presented a progressive bleeding tendency, characterized recurrent subcutaneous hemorrhages and cerebral hemorrhage. Mixing and infusion studies suggested the presence of an inhibitor directed against vWF:RCo activity of von Willebrand factor (vWF) without significant inhibition of the FVIII:C. The inhibitor was identified as an antibody of IgG class. The inhibitor inhibited the interaction of vWF in the presence of ristocetin and that of asialo-vWF with GPIb while it partially blocked botrocetin-mediated interaction of vWF to GPIb. The inhibitor reacted with native vWF, the 39/34kDa fragment (amino acids [aa] 480/ 481-718) and the recombinant vWF fragment (MalE-rvWF508-704), but not with Fragment III-T2 (heavy chains, aa 273-511; light chains, aa 674-728). A synthetic peptide (aa 514-542) did not inhibit vWF-inhibitor complex formation. We conclude that this is the first autoantibody of class IgG from human origin that recognizes the sequence in the A1 loop of vWF, resulting in a virtual absence of functional vWF and a concomitant severe bleeding tendency although recognition site is different from the residues 514-542 which is crucial for vWF-GPIb interaction.

[1]  J. Ware,et al.  Structure and Function of von Willebrand Factor , 1992, Thrombosis and Haemostasis.

[2]  A. Yoshioka,et al.  Inhibition assay for the binding of biotinylated von Willebrand factor to platelet-bound microtiter wells in the presence of ristocetin or botrocetin. , 1996, Analytical biochemistry.

[3]  H. Mohri,et al.  Acquired type 2A von Willebrand disease in chronic myelocytic leukemia. , 1996, Hematopathology and molecular hematology.

[4]  H. Mohri,et al.  Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  D. Meyer,et al.  Structure-Function Relationship of the A1 Domain of von Willebrand Factor , 1995, Thrombosis and Haemostasis.

[6]  P. V. van Genderen,et al.  Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. , 1994, Blood.

[7]  J. Sadler,et al.  A Revised Classification of von Willebrand Disease , 1994, Thrombosis and Haemostasis.

[8]  R. Handin,et al.  The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX. The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein. , 1993, The Journal of biological chemistry.

[9]  C. Ward,et al.  Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin. , 1992, Biochemistry.

[10]  A. Schreiber,et al.  Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. , 1991, Biochemistry.

[11]  K Watanabe,et al.  The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. , 1991, The Journal of clinical investigation.

[12]  J. Gorman,et al.  Cross-linking of a monomeric 39/34-kDa dispase fragment of von Willebrand factor (Leu-480/Val-481-Gly-718) to the N-terminal region of the alpha-chain of membrane glycoprotein Ib on intact platelets with bis(sulfosuccinimidyl) suberate. , 1989, Biochemistry.

[13]  H. Mohri,et al.  Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. , 1989, The Journal of biological chemistry.

[14]  R. Houghten,et al.  Structure of the von Willebrand factor domain interacting with glycoprotein Ib. , 1988, The Journal of biological chemistry.

[15]  J. Batlle,et al.  Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease. , 1988, Blood.

[16]  K. Titani,et al.  The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. , 1986, The Journal of biological chemistry.

[17]  K. Titani,et al.  Limited proteolysis of human von Willebrand factor by Staphylococcus aureus V-8 protease: isolation and partial characterization of a platelet-binding domain. , 1986, Biochemistry.

[18]  I. Kjønniksen,et al.  Visualization of von Willebrand Factor Multimers by Enzyme-Conjugated Secondary Antibodies , 1986, Thrombosis and Haemostasis.

[19]  K. Titani,et al.  von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. , 1986, The Journal of biological chemistry.

[20]  S. Shapiro,et al.  Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent. , 1981, The Journal of clinical investigation.

[21]  P. Mannucci,et al.  Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. , 1981, Blood.

[22]  P. Mannucci,et al.  Familial incidence of precipitating antibodies in von Willebrand's disease: a study of four cases. , 1979, The Journal of laboratory and clinical medicine.

[23]  S. Pizzo,et al.  Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. , 1979, The Journal of clinical investigation.

[24]  M. Read,et al.  Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Jenkin,et al.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. , 1978, Immunochemistry.

[26]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[27]  P. Fraker,et al.  PROTEIN AND CELL MEMBRANE IODINATION WITH A SPARINGLY SOLUBLE CHLOROAMIDE , 1978 .

[28]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[29]  R. Grant,et al.  A Method for Assaying von Willebrand Factor (Ristocetin Cofactor) , 1975, Thrombosis and Haemostasis.

[30]  W. W. Duke.  The Relation of Blood Platelets to Hemorrhagic Disease: Description of a Method for Determining the Bleeding Time and Coagulation Time and Report of Three Cases of Hemorrhagic Disease Relieved by Transfusion , 1910 .

[31]  H. Gralnick,et al.  A monomeric von Willebrand factor fragment, Leu-504-Ser-728, inhibits von Willebrand factor interaction with glycoprotein lb-IX , 2022 .